Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xiaoer Yinlian Granules
- Development stage
- Phase 2
- Lead developer
- Yili Pharmaceutical
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Xiaoer Yinlian Granules (小儿银连颗粒) is a traditional Chinese medicine (TCM) herbal formulation developed by Yili Pharmaceutical for the treatment of pediatric acute upper respiratory tract infections (common cold) presenting with a wind-heat pattern. The formulation is designed to clear heat, resolve toxicity, and relieve symptoms such as mild to moderate fever, cough, and sore throat in children. It is currently undergoing Phase II clinical evaluation in China to assess its safety and efficacy in pediatric patients aged 7 to 12 years.
- Other names
- Xiaoer Yinlian Granule小儿银连颗粒
Beyond the preview
Go deeper on Xiaoer Yinlian Granules.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Xiaoer Yinlian Granules.